1. Home
  2. TECH vs VTRS Comparison

TECH vs VTRS Comparison

Compare TECH & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TECH
  • VTRS
  • Stock Information
  • Founded
  • TECH 1976
  • VTRS 1961
  • Country
  • TECH United States
  • VTRS United States
  • Employees
  • TECH N/A
  • VTRS N/A
  • Industry
  • TECH Biotechnology: Biological Products (No Diagnostic Substances)
  • VTRS Medicinal Chemicals and Botanical Products
  • Sector
  • TECH Health Care
  • VTRS Health Care
  • Exchange
  • TECH Nasdaq
  • VTRS Nasdaq
  • Market Cap
  • TECH 9.9B
  • VTRS 11.1B
  • IPO Year
  • TECH 1989
  • VTRS N/A
  • Fundamental
  • Price
  • TECH $63.94
  • VTRS $10.29
  • Analyst Decision
  • TECH Buy
  • VTRS Hold
  • Analyst Count
  • TECH 13
  • VTRS 6
  • Target Price
  • TECH $70.58
  • VTRS $11.17
  • AVG Volume (30 Days)
  • TECH 2.3M
  • VTRS 6.9M
  • Earning Date
  • TECH 11-05-2025
  • VTRS 11-06-2025
  • Dividend Yield
  • TECH 0.50%
  • VTRS 4.67%
  • EPS Growth
  • TECH N/A
  • VTRS N/A
  • EPS
  • TECH 0.46
  • VTRS N/A
  • Revenue
  • TECH $1,219,635,000.00
  • VTRS $14,115,700,000.00
  • Revenue This Year
  • TECH $3.72
  • VTRS N/A
  • Revenue Next Year
  • TECH $7.67
  • VTRS $1.61
  • P/E Ratio
  • TECH $139.00
  • VTRS N/A
  • Revenue Growth
  • TECH 5.23
  • VTRS N/A
  • 52 Week Low
  • TECH $46.01
  • VTRS $6.85
  • 52 Week High
  • TECH $80.80
  • VTRS $13.55
  • Technical
  • Relative Strength Index (RSI)
  • TECH 62.22
  • VTRS 57.00
  • Support Level
  • TECH $58.15
  • VTRS $10.18
  • Resistance Level
  • TECH $66.96
  • VTRS $10.50
  • Average True Range (ATR)
  • TECH 1.86
  • VTRS 0.21
  • MACD
  • TECH 0.20
  • VTRS 0.04
  • Stochastic Oscillator
  • TECH 66.85
  • VTRS 72.73

About TECH Bio-Techne Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Share on Social Networks: